Why Is TWIST BIOSCIENCE COR (TWST) Stock Up Today?

Twist Bioscience (TWST) shares climbed 8.60% to $165.13, driven by a fresh initiation from Jefferies and continued momentum in the AI drug discovery sector. The stock opened with a 2.5% gap above the prior close, reaching a session high of $165.44 at 10:00 AM ET. This move occurred despite a recent 16.7% decline over the last eight trading sessions.

What Happened

Jefferies initiated coverage on Twist Bioscience with a Hold rating and a $150 price target, citing valuation concerns. This action coincided with a broader narrative that the company’s valuation is stretched as AI hype outpaces near-term revenue reality. While Jefferies issued a cautious stance, Barclays maintained an Overweight rating and raised its price target to $215, highlighting divergent views on the stock’s potential. The company remains unprofitable, with a trailing twelve-month EPS of -$2.23 and a net margin of -31.7%. Revenue growth of 19.2% over the same period suggests underlying business expansion, yet the market’s focus remains on the premium placed on its AI capabilities.

What The Data Shows

The stock printed 14 fresh 52-week highs on October 9, 2026, indicating strong recent momentum before the current session. The 52-week range spans from $23.30 to $219.71, placing the current price near the upper end of this interval. Intraday volume was 0.5 million shares, which is 0.3 times the three-month daily average, suggesting the price increase was not driven by a surge in trading activity. Insider activity has been heavily skewed toward selling, with 37 sales totaling $119.8 million in the last 90 days and no purchases. Recent Form 4 filings show sales by CEO Emily M. Leproust, SVP of HR Paula Green, and President and COO Patrick John Finn in early October. The stock’s beta of 2.19 indicates high volatility relative to the broader market.

What To Watch

Investors will monitor how the stock reacts to the Jefferies initiation and whether the valuation concerns cited by analysts dampen the recent rally. The divergence between Jefferies’ $150 target and Barclays’ $215 target highlights the uncertainty surrounding the stock’s fair value. Future earnings reports will be critical in determining if revenue growth can support the current market capitalization of $9.8 billion.